Bhutan vs Latin America & the Caribbean (IDA & IBRD countries): Immunization, Hib3
Immunization, Hib3 over time
- Bhutan
- Latin America & the Caribbean (IDA & IBRD countries)
How they compare
Bhutan currently reports 98.0% against 81.6% in Latin America & the Caribbean (IDA & IBRD countries), a difference of 16.4%.
That makes Bhutan's figure about 1.2 times Latin America & the Caribbean (IDA & IBRD countries)'s.
Across all 13 years both countries report, Bhutan has been ahead every year.
Bhutan ranks 20th and Latin America & the Caribbean (IDA & IBRD countries) ranks 23rd of 191 countries.
Bhutan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bhutan | Latin America & the Caribbean (IDA & IBRD countries) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 97.8% | 87.1% | 10.7% | Bhutan |
| 2020s | 97.8% | 78.7% | 19.1% | Bhutan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Bhutan or Latin America & the Caribbean (IDA & IBRD countries)?
- Bhutan, at 98.0% against 81.6% in Latin America & the Caribbean (IDA & IBRD countries) as of 2024.
- What is the difference in immunization, hib3 between Bhutan and Latin America & the Caribbean (IDA & IBRD countries)?
- 16.4%, with Bhutan ahead.
- How many years of comparable data are there for Bhutan and Latin America & the Caribbean (IDA & IBRD countries)?
- 13 years are reported by both, from 2012 to 2024.
- How do Bhutan and Latin America & the Caribbean (IDA & IBRD countries) rank globally for immunization, hib3?
- Bhutan ranks 20th and Latin America & the Caribbean (IDA & IBRD countries) ranks 23rd of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.